Man Group’s Viridian Therapeutics VRDN Stock Holding History

Man Group’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$197K	Buy	+10,740	New	+$173K	﹤0.01%	2269
2026 Q1	–	Sell	-18,200	Closed	-$566K	–	2598
2025 Q4	$566K	Buy	+18,200	New	+$499K	﹤0.01%	1860
2023 Q3	–	Sell	-20,400	Closed	-$389K	–	1470
2023 Q2	$485K	Buy	+20,400	New	+$523K	﹤0.01%	1596
2018 Q4	–	Sell	-882	Closed	-$74K	–	2130
2018 Q3	$74K	Sell	882 -126	-13%	-$11.9K	﹤0.01%	2056
2018 Q2	$97K	Sell	1,008 -1,147	-53%	-$121K	﹤0.01%	2071
2018 Q1	$227K	Buy	+2,155	New	+$234K	﹤0.01%	1899

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Man Group's VRDN Position: Q2 2026 in Review

Man Group opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 10,740 shares worth $197K. The stake represents ﹤0.01% of the portfolio and ranks #2269 among its holdings. This is a return to the name: Man Group previously reported a position in VRDN as recently as Q4 2025.

Man Group first reported a position in VRDN in Q1 2018 and has held it in 6 quarters since. The position peaked at $566K in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Man Group held 10,740 shares of Viridian Therapeutics worth $197K as of Q2 2026.
Viridian Therapeutics was a new Man Group position in Q2 2026.
Viridian Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2269 holding.
Man Group first reported a position in Viridian Therapeutics in Q1 2018 and has held it in 6 quarters since.
Man Group's Viridian Therapeutics position peaked at $566K in Q4 2025.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.